Posted by Michael Wonder on 30 Sep 2020
New dual therapy PBS restrictions for pulmonary arterial hypertension medicines
30 September 2020 - Access to medicines for pulmonary arterial hypertension has improved as an outcome of the post-market review of medicines for pulmonary arterial hypertension.
Effective 1 October 2020, patients with pulmonary arterial hypertension with World Health Organisation functional class III or IV symptoms will have access to endothelin receptor antagonist and phosphodiesterase-5 inhibitor medicines for dual therapy.
